The coronavirus disease 2019 (COVID-19) has swept the world, posing a serious threat to people's lives and health. Several cases of COVID-19 infection in renal transplant recipients (RTRs) have been reported, but the treatment and prognosis have not been fully elucidated. We followed-up with RTRs infected with SARS-CoV2 in our center and classified them as five clinical types—asymptomatic, mild, moderate, severe, and critical. The immunosuppressive agents were not adjusted in asymptomatic carriers and mild patients, the former was mainly treated by isolation, and the latter was treated by low-dose intravenous immunoglobulin (IVIG) to enhance immunity. For moderate or severe patients, the immunosuppressive agents were largely reduced or even interrupted, low-dose IVIG was adopted, and low-dose methylprednisolone (MP) was used to inhibit inflammation and rejection. Immunosuppressants were discontinued early in critical patients; IVIG, high-dose MP, and antibiotics were used. Meanwhile, all patients received at least one antiviral drugs. After aggressive treatment, three patients developed acute kidney injury, and two showed reversal, while the remaining one lost the allograft kidney; one patient died, while other patients were discharged. For different clinical types of RTRs infected with COVID-19, personalized therapies were essential, Meanwhile, patients with COVID-19 infection may have different outcomes due to their different clinical manifestations.

2019年冠状病毒病（COVID-19）席卷全球，对人们的生命健康构成严重威胁。已经报道了几例肾移植受者 (RTR) 感染 COVID-19 的病例，但治疗和预后尚未完全阐明。我们跟进了我们中心感染 SARS-CoV2 的 RTR，并将其分为五种临床类型——无症状、轻度、中度、重度和危重症。无症状携带者和轻症患者免疫抑制剂不作调整，前者以隔离治疗为主，后者以小剂量静脉注射免疫球蛋白（IVIG）增强免疫力治疗。对于中重度患者，免疫抑制剂大幅度减量甚至停用，采用小剂量IVIG，低剂量甲泼尼龙（MP）用于抑制炎症和排斥反应。重症患者早期停用免疫抑制剂；使用了 IVIG、高剂量 MP 和抗生素。同时，所有患者都接受了至少一种抗病毒药物。积极治疗后，3例出现急性肾损伤，2例出现逆转，1例移植肾丢失；一名患者死亡，而其他患者出院。对于感染COVID-19的不同临床类型的RTR，个性化治疗至关重要，同时，COVID-19感染患者由于其不同的临床表现可能有不同的结果。所有患者都至少接受了一种抗病毒药物。积极治疗后，3例出现急性肾损伤，2例出现逆转，1例移植肾丢失；一名患者死亡，而其他患者出院。对于感染COVID-19的不同临床类型的RTR，个性化治疗至关重要，同时，COVID-19感染患者由于其不同的临床表现可能有不同的结果。所有患者都至少接受了一种抗病毒药物。积极治疗后，3例出现急性肾损伤，2例出现逆转，1例移植肾丢失；一名患者死亡，而其他患者出院。对于感染COVID-19的不同临床类型的RTR，个性化治疗至关重要，同时，COVID-19感染患者由于其不同的临床表现可能有不同的结果。